A US judge narrowed a long-running antitrust case where aluminum purchasers accused Goldman Sachs , JPMorgan Chase, and the mining company Glencore of conspiring to drive up the metal’s price by reducing supply, reported Reuters.
US District Judge Paul Engelmayer said many purchasers lacked standing to sue because they had bought aluminum primarily from smelters such as Alcoa and Rio Tinto Alcan rather than directly from the defendants, and thus did not qualify as “efficient enforcers” of antitrust laws.
In a 66-page decision, the Manhattan judge also wrote that pricing decisions by the smelters appeared to be a big factor in the prices ultimately charged, and that those prices were “not the inevitable result of defendants’ alleged conspiracy.”
The purchasers had accused banks and commodity trading, mining, and metals warehousing companies of conspiring to hoard aluminum when prices were low roughly a decade ago.
They said this resulted in delays in processing orders and higher storage costs, raising the cost of making cabinets, flashlights, soda cans, and other goods containing aluminum.
Engelmayer dismissed all claims by several individual purchasers including Eastman Kodak and Fujifilm, as well as claims by some “first level” purchasers whose motion for class certification he had denied last July.
The judge said Reynolds Consumer Products and two other plaintiffs that transacted directly with the defendants could still pursue their cases.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan